Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3086655
Max Phase: Preclinical
Molecular Formula: C66H110N18O19
Molecular Weight: 1459.71
Molecule Type: Protein
Associated Items:
ID: ALA3086655
Max Phase: Preclinical
Molecular Formula: C66H110N18O19
Molecular Weight: 1459.71
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O)C(C)C)C(C)C
Standard InChI: InChI=1S/C66H110N18O19/c1-31(2)24-39(67)54(91)78-43(25-32(3)4)64(101)84-23-17-21-46(84)60(97)75-40(20-16-22-71-66(69)70)56(93)80-49(33(5)6)61(98)73-36(11)53(90)76-42(27-47(68)88)55(92)72-28-48(89)74-44(29-85)58(95)79-45(30-86)59(96)77-41(26-38-18-14-13-15-19-38)57(94)81-50(34(7)8)62(99)83-52(37(12)87)63(100)82-51(35(9)10)65(102)103/h13-15,18-19,31-37,39-46,49-52,85-87H,16-17,20-30,67H2,1-12H3,(H2,68,88)(H,72,92)(H,73,98)(H,74,89)(H,75,97)(H,76,90)(H,77,96)(H,78,91)(H,79,95)(H,80,93)(H,81,94)(H,82,100)(H,83,99)(H,102,103)(H4,69,70,71)/t36-,37+,39-,40-,41-,42-,43-,44-,45-,46-,49-,50-,51-,52-/m0/s1
Standard InChI Key: HTEFIIKKKYERGJ-LCNGWHBBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1459.71 | Molecular Weight (Monoisotopic): 1458.8195 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Heard KR, Wu W, Li Y, Zhao P, Woznica I, Lai JH, Beinborn M, Sanford DG, Dimare MT, Chiluwal AK, Peters DE, Whicher D, Sudmeier JL, Bachovchin WW.. (2013) A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates., 56 (21): [PMID:24044354] [10.1021/jm400423p] |
Source(1):